Daiichi aims for 60 percent growth

Daiichi Sankyo says it's ready for it's close-up. The company got FDA approval last week for a combo remedy for hypertension, Azor, and now it's meeting with its Congressman to talk about adding new jobs at its New Jersey HQ. Perhaps most surprising is its sales-growth target: a whopping 60 percent over the next three years, based on its hopes for Azor and two other meds coming up the pipeline.

Not exactly a household name in the U.S., Daiichi Sankyo has historically developed drugs for licensing to other companies, including Pravachol, a statin sold by Bristol-Myers Squibb; and Levaquin, an antibiotic marketed by Johnson & Johnson. Now, to do more marketing on its own, Daiichi Sankyo has more than doubled its sales force. They'll have to hoof it to meet that ambitious growth target.

- check out Daiichi Sankyo's press release
- read the article in PharmaTimes

Related Articles:
Daiichi Sankyo buys OTC business. Report
Daiichi Sankyo invests in venture fund. Report
Big Pharma brings home the cash, slices payroll. Report

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.